finasteride

• peak urine flow and nocturia improvement

  unclear

  Both doxazosin and terazosin were significantly more likely than finasteride to improve peak urine flow and nocturia, versus finasteride

  PMID:20927745 · one of two readings recorded this

• risk of BPH progression (acute urinary retention, surgical intervention, symptom-score increase)

  decreases

  Finasteride consistently improved urinary symptom scores more than placebo in trials of > 1 year duration, and significantly lowered the risk of BPH progression (acute urinary retention, risk of surgical intervention, ≥ 4 point increase in the AUASI/IPSS)

  PMID:20927745 · one of two readings recorded this

• urinary symptom improvement (>= 4 point)

  no effect

  Finasteride + doxazosin and doxazosin monotherapy improved urinary symptoms equally well (≥ 4 point improvement)

  PMID:20927745 · one of two readings recorded this

• urinary symptom score (AUA/IPSS)

  decreases

  Finasteride consistently improved urinary symptom scores more than placebo in trials of > 1 year duration, and significantly lowered the risk of BPH progression (acute urinary retention, risk of surgical intervention, ≥ 4 point increase in the AUASI/IPSS)

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, long term

  decreases

  Comparing short to long-term therapy, finasteride does not improve symptoms significantly better than placebo at the short term, but in the long term it does, although the magnitude of differences was very small (from < 1.0 point to 2.2 points)

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, long term

  unclear

  Doxazosin improves symptoms better than finasteride both short and long term, with the magnitude of differences ∼2.0 points and 1.0 point, respectively

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, long term

  unclear

  Finasteride + doxazosin improves scores versus finasteride alone at both short and long term, with mean differences ∼2.0 points for both time points

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, short term

  no effect

  Comparing short to long-term therapy, finasteride does not improve symptoms significantly better than placebo at the short term, but in the long term it does, although the magnitude of differences was very small (from < 1.0 point to 2.2 points)

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, short term

  unclear

  Doxazosin improves symptoms better than finasteride both short and long term, with the magnitude of differences ∼2.0 points and 1.0 point, respectively

  PMID:20927745 · one of two readings recorded this

• urinary symptom score, short term

  unclear

  Finasteride + doxazosin improves scores versus finasteride alone at both short and long term, with mean differences ∼2.0 points for both time points

  PMID:20927745 · one of two readings recorded this

• urinary symptom score

  unclear

  In comparison to alpha-blocker monotherapy, finasteride was less effective than either doxazosin or terazosin, but equally effective compared to tamsulosin.

  PMID:20927745 · one of two readings recorded this

• urinary symptom score

  no effect

  In comparison to alpha-blocker monotherapy, finasteride was less effective than either doxazosin or terazosin, but equally effective compared to tamsulosin.

  PMID:20927745 · one of two readings recorded this

• urinary symptom score

  unclear

  In comparison to alpha-blocker monotherapy, finasteride was less effective than either doxazosin or terazosin, but equally effective compared to tamsulosin.

  PMID:20927745 · one of two readings recorded this

• urinary symptom scores, validated symptom scale such as AUA/IPSS, finasteride versus placebo in trials longer than 1 year

  increases, improved urinary symptom scores more than placebo in trials of > 1 year duration

  Not recorded as a finding: the paper never states the instrument the node requires

  Finasteride consistently improved urinary symptom scores more than placebo in trials of > 1 year duration, and significantly lowered the risk of BPH progression (acute urinary retention, risk of surgical intervention, ≥ 4 point increase in the AUASI/IPSS).

  PMID:20927745 · one of two readings recorded this

• high-grade prostate cancer risk, increase in androstenedione

  no effect

  There was no association between increase in androstenedione level and high-grade prostate cancer

  PMID:25733274 · one of two readings recorded this

• low-grade prostate cancer risk, highest vs lowest tertile of absolute change in androstenedione

  decreases

  For low-grade cancer, this association was more pronounced for both the absolute change (OR=0.42, 95% CI=0.19–0.94) and the percent change (OR=0.46, 95% CI=0.22–0.98) in androstenedione

  PMID:25733274 · one of two readings recorded this

• low-grade prostate cancer risk, highest vs lowest tertile of percent change in androstenedione

  decreases

  For low-grade cancer, this association was more pronounced for both the absolute change (OR=0.42, 95% CI=0.19–0.94) and the percent change (OR=0.46, 95% CI=0.22–0.98) in androstenedione

  PMID:25733274 · one of two readings recorded this

• overall prostate cancer risk, highest vs lowest tertile of absolute change in androstenedione

  decreases

  There was a 56% decreased overall prostate cancer risk (OR=0.44, 95% CI=0.21–0.95) when men in the highest tertile were compared to men in the lowest tertile

  PMID:25733274 · one of two readings recorded this

• overall prostate cancer risk, highest vs lowest tertile of baseline serum androstenedione

  no effect

  In the finasteride group, there was a 23% statistically non-significant decreased risk of prostate cancer risk when the highest tertile of serum andostenedione was compared to the lowest tertile

  PMID:25733274 · one of two readings recorded this

• overall prostate cancer risk, highest vs lowest tertile of percent change in androstenedione

  no effect

  A similar association was observed for the percent change in androstenedione (OR=0.56, 95% CI=0.29–1.08)

  PMID:25733274 · one of two readings recorded this

• serum androstenedione change from baseline to year 3

  increases

  There was an approximate 22% increase in serum androstenedione in both cases and controls

  PMID:25733274 · one of two readings recorded this

• serum androstenedione concentration by radioimmunoassay, change from baseline to year 3 on finasteride 5 mg/day, nested case-control within the PCPT

  increases, approximate 22% increase from baseline

  Not recorded as a finding: this platform holds no node for the endpoint

  There was an approximate 22% increase in serum androstenedione in both cases and controls.

  PMID:25733274 · one of two readings recorded this

• serum androstenedione concentration change from baseline to year 3, radioimmunoassay after Celite column chromatography, finasteride 5 mg daily in the PCPT nested case-control set

  increases

  Not recorded as a finding: this platform holds no node for the endpoint

  There was an approximate 22% increase in serum androstenedione in both cases and controls.

  PMID:25733274 · one of two readings recorded this

• adherence by pill diary and pill count

  As measured by pill diary and pill count, adherence was 97.8%

  PMID:27322462 · one of two readings recorded this

• age at enrolment, median

  p = 0.005

  Men assigned to the finasteride arm were younger than those in the placebo arm (median age, 59 years [range, 45–73] versus 62 years [range, 48–73]; P = 0.005)

  PMID:27322462 · one of two readings recorded this

• age at enrolment, median

  p = 0.004

  The finasteride group was younger than the placebo group (median age, 58 years [range, 45–73] versus 63 years [range, 48–73]; P = 0.004)

  PMID:27322462 · one of two readings recorded this

• androgen receptor expression by immunohistochemistry in Gleason grade 4 tumour areas

  decreases, median 63.7% versus 75.9% in GG4 areas, finasteride versus placebo, p = 0.04

  Not recorded as a finding: no outcome node for tissue androgen receptor expression; grade-4 subgroup only

  However, although no significant difference was found in GG3 tumors between the groups (median, 75.2% versus 78.3%, P = 0.41) (Table 2; Supplementary Fig. S2A), the level of AR in finasteride-exposed GG4 tumors was significantly lower than that in placebo group GG4 tumors (median, 63.7% versus 75.9%, P = 0.04) (Supplementary Fig. S2B).

  PMID:27322462 · one of two readings recorded this

• AR expression in GG4 vs GG3 tumor areas, within finasteride arm

  no effect, p = 0.09

  AR expression in GG4 tumor areas was numerically lower than it was in GG3 tumor areas (median, 63.7% versus 75.2%, P = 0.09)

  PMID:27322462 · one of two readings recorded this

• AR expression in Gleason grade 3 tumor areas

  no effect, p = 0.41

  no significant difference was found in GG3 tumors between the groups (median, 75.2% versus 78.3%, P = 0.41)

  PMID:27322462 · one of two readings recorded this

• AR expression in Gleason grade 4 tumor areas

  decreases, p = 0.04

  the level of AR in finasteride-exposed GG4 tumors was significantly lower than that in placebo group GG4 tumors (median, 63.7% versus 75.9%, P = 0.04)

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 expression by immunohistochemistry in Gleason grade 3 and 4 tumour areas of prostatectomy specimens

  increases, significantly higher in GG3 and GG4 tumours from the finasteride group than placebo

  Not recorded as a finding: no outcome node for tissue cleaved caspase 3 immunohistochemistry

  By comparison, the cleaved caspase 3 level was significantly higher in GG3 (median, 0.2% versus 0.08%, P = 0.03) and GG4 (median, 0.06% versus 0.04%, P = 0.02) tumors from the finasteride group than in those from the placebo group (Table 3; Supplementary Figs. 2A and).

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 expression (percentage immunoreactive cells, immunohistochemistry) in Gleason grade 3 and 4 tumour areas

  increases, higher in finasteride arm than placebo in both grades

  Not recorded as a finding: no outcome node for tumour tissue apoptosis marker by immunohistochemistry

  By comparison, the cleaved caspase 3 level was significantly higher in GG3 (median, 0.2% versus 0.08%, P = 0.03) and GG4 (median, 0.06% versus 0.04%, P = 0.02) tumors from the finasteride group than in those from the placebo group (Table 3; Supplementary Figs. 2A and).

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 level, GG3 vs GG4 tumor areas, finasteride arm

  decreases, p = 0.001

  the cleaved caspase 3 level was significantly higher in GG3 tumors than in GG4 tumors (finasteride: 0.2% versus 0.06%, P < 0.001; placebo: 0.08% versus 0.04%, P < 0.001)

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 level, GG3 vs GG4 tumor areas, placebo arm

  decreases, p = 0.001

  the cleaved caspase 3 level was significantly higher in GG3 tumors than in GG4 tumors (finasteride: 0.2% versus 0.06%, P < 0.001; placebo: 0.08% versus 0.04%, P < 0.001)

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 level in GG3 tumor areas, finasteride vs placebo

  increases, p = 0.03

  the cleaved caspase 3 level was significantly higher in GG3 (median, 0.2% versus 0.08%, P = 0.03) and GG4 (median, 0.06% versus 0.04%, P = 0.02) tumors from the finasteride group than in those from the placebo group

  PMID:27322462 · one of two readings recorded this

• cleaved caspase 3 level in GG4 tumor areas, finasteride vs placebo

  increases, p = 0.02

  the cleaved caspase 3 level was significantly higher in GG3 (median, 0.2% versus 0.08%, P = 0.03) and GG4 (median, 0.06% versus 0.04%, P = 0.02) tumors from the finasteride group than in those from the placebo group

  PMID:27322462 · one of two readings recorded this

• GG3 and GG4 tumor areas available for molecular marker analysis (GG3)

  In the finasteride arm and placebo arm, there were 67 and 75 GG3 tumor areas and 57 and 61 GG4 tumor areas, respectively

  PMID:27322462 · one of two readings recorded this

• GG3 and GG4 tumor areas available for molecular marker analysis (GG4)

  In the finasteride arm and placebo arm, there were 67 and 75 GG3 tumor areas and 57 and 61 GG4 tumor areas, respectively

  PMID:27322462 · one of two readings recorded this

• patient tumor volume, median, all patients

  no effect, p = 0.73

  Patient tumor volume median values were similar overall (finasteride, 1.0 mL [range, 0–9.3 mL]; placebo, 0.8 mL [range, 0–10.4 mL]; P = 0.73)

  PMID:27322462 · one of two readings recorded this

• patient tumor volume, median, biomarker subgroup

  no effect, p = 0.79

  tumor volume median values for the biomarker subgroup were similar overall (finasteride, 0.9 mL [range, 0.01–7.8 mL]; placebo, 0.8 mL [range, 0.01–5.5 mL]; P = 0.79)

  PMID:27322462 · one of two readings recorded this

• patients randomised and evaluable

  n = 183

  Of 2761 patients screened, 204 were randomized between February 2007 and March 2012, and 183 (89.7%) received treatment and were evaluable

  PMID:27322462 · one of two readings recorded this

• serum DHT after intervention

  decreases, p = 0.001

  DHT levels (10 ng/dL versus 27 ng/dL; P < 0.001)

  PMID:27322462 · one of two readings recorded this

• serum PSA after intervention

  decreases, p = 0.001

  significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL; P < 0.001)

  PMID:27322462 · one of two readings recorded this

• serum testosterone after intervention

  increases, p = 0.04

  a significantly higher testosterone level (382 ng/dL versus 327 ng/dL; P = 0.04)

  PMID:27322462 · one of two readings recorded this

• tumor volume of peripheral zone cancer foci, median, all patients

  no effect, p = 0.75

  the peripheral zone (finasteride, 0.6 mL [range, 0–9.3 mL]; placebo, 0.5 mL [range, 0–9 mL]; P = 0.75)

  PMID:27322462 · one of two readings recorded this

• tumor volume of peripheral zone cancer foci, median, biomarker subgroup

  no effect, p = 0.4

  the peripheral zone (finasteride, 0.6 mL [range, 0.01–7.8 mL]; placebo, 0.7 mL [range, 0–4.2 mL]; P = 0.40)

  PMID:27322462 · one of two readings recorded this

• tumor volume of transition zone cancer foci, median, all patients

  no effect, p = 0.84

  the transition zone (finasteride, 0.0 mL [range, 0–6 mL]; placebo, 0.0 mL [range, 0–10.4 mL]; P = 0.84)

  PMID:27322462 · one of two readings recorded this

• tumor volume of transition zone cancer foci, median, biomarker subgroup

  no effect, p = 0.43

  the transition zone (finasteride, 0.03 mL [range, 0–5.8 mL]; placebo, 0 mL [range, 0–3.6 mL]; P = 0.43)

  PMID:27322462 · one of two readings recorded this

• baseline serum PSA, cases vs controls

  increases, p = 0.0001

  Mean baseline serum PSA was higher among cases than controls (P<0.0001)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk, IL10 haplotype ATTCCGT vs most common haplotype

  no effect

  appeared to be associated with risk of total (OR=2.11, 95% CI 0.97–4.63), lower- (OR=2.39, 95%CI 1.03–5.56), and higher- (OR=1.89, 95% CI 0.64–5.59) grade disease

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  increases, p = 0.04

  The minor allele (T) of rs2430561 in IFNG was positively associated with risk of total (OR=1.20, 95% CI 0.99–1.46, P-trend=0.1) and higher-grade (OR=1.33 95%CI 1.02–1.74; P-trend=0.04)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  decreases, p = 0.02

  In all men, the minor allele (G) of rs1800896 in IL10 was inversely associated with risk of higher-grade disease (OR=0.77 0.61–0.96; P-trend= 0.02)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  the minor allele (C) was possibly positively associated with higher-grade disease (OR=1.31, 95% CI 0.94–1.82, P-trend= 0.1; Supplement Table 4) among men with low PSA

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  increases, p = 0.03

  The minor allele (T) of rs2243250 in IL4 was positively associated with higher-grade (OR=1.46, 95% CI 1.03–2.08; P-trend 0.03

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  decreases, p = 0.02

  the minor alleles of rs1800795 (C: OR=0.70, 95% CI 0.51–0.94; P-trend=0.02; Supplement Table 4) and of rs1800797 (A: OR=0.72, 95% CI 0.53–0.98, P-trend=0.04; Supplement Table 4)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  decreases, p = 0.04

  the minor alleles of rs1800795 (C: OR=0.70, 95% CI 0.51–0.94; P-trend=0.02; Supplement Table 4) and of rs1800797 (A: OR=0.72, 95% CI 0.53–0.98, P-trend=0.04; Supplement Table 4)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.06

  The minor allele (A) of rs4073 in IL8 was possibly inversely associated with total prostate cancer (OR=0.89, CI: 0.75–1.04, P-trend=0.1) and higher-grade disease (OR=0.81, CI: 0.64–1.01, P-trend=0.06)

  PMID:28317149 · one of two readings recorded this

• higher-grade prostate cancer risk per minor allele, finasteride arm

  decreases, p = 0.03

  The minor allele (C) of rs3747531 in MSR1 was possibly inversely associated with total (OR=0.77, 95% CI 0.55–1.08, P-trend=0.1) and especially higher-grade (OR=0.55, 95% CI 0.32–0.95, P-trend=0.03)

  PMID:28317149 · one of two readings recorded this

• IL10 haplotype distribution, higher-grade cases vs controls with low PSA

  unclear, p = 0.07

  except possibly between higher-grade cases and controls with low PSA (P=0.07)

  PMID:28317149 · one of two readings recorded this

• IL10 haplotype distribution, higher-grade cases vs controls

  no effect, p = 0.2

  between total cases and controls (score test P=0.2), lower-grade cases and controls (score test P=0.4), or higher-grade cases and controls (P=0.2)

  PMID:28317149 · one of two readings recorded this

• IL10 haplotype distribution, lower-grade cases vs controls

  no effect, p = 0.4

  between total cases and controls (score test P=0.2), lower-grade cases and controls (score test P=0.4), or higher-grade cases and controls (P=0.2)

  PMID:28317149 · one of two readings recorded this

• IL10 haplotype distribution, total cases vs controls

  no effect, p = 0.2

  between total cases and controls (score test P=0.2), lower-grade cases and controls (score test P=0.4), or higher-grade cases and controls (P=0.2)

  PMID:28317149 · one of two readings recorded this

• lower-grade prostate cancer risk, IL10 haplotype ATTCCGT vs most common haplotype

  increases

  appeared to be associated with risk of total (OR=2.11, 95% CI 0.97–4.63), lower- (OR=2.39, 95%CI 1.03–5.56), and higher- (OR=1.89, 95% CI 0.64–5.59) grade disease

  PMID:28317149 · one of two readings recorded this

• lower-grade prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.09

  The minor allele (T) of rs1800871 in IL10 was possibly positively associated with total prostate cancer (OR=1.25, CI: 0.99–1.58, P-trend=0.1) and lower-grade disease (OR=1.26, CI: 0.96–1.64, P-trend=0.09)

  PMID:28317149 · one of two readings recorded this

• lower-grade prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.09

  the minor allele (A) of rs1800872 in IL10 was possibly positively associated with overall prostate cancer (OR=1.20, CI: 0.99–1.46, P-trend=0.1) and lower-grade (OR=1.20, CI: 0.96–1.50, P-trend=0.09)

  PMID:28317149 · one of two readings recorded this

• lower-grade prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.07

  The minor allele (T) of rs1143634 in IL1β was possibly inversely associated with total prostate cancer (OR=0.84, CI: 0.70–1.02, P-trend=0.1) and lower-grade (OR=0.82, CI: 0.66–1.02, P-trend=0.07)

  PMID:28317149 · one of two readings recorded this

• serum PSA trend with minor allele number in controls

  increases, p = 0.1

  and possibly in rs3212227 in IL12(p40) (C; P-trend=0.1) and tagSNP rs3021094 in IL10 (C; P-trend=0.1)

  PMID:28317149 · one of two readings recorded this

• serum PSA trend with minor allele number in controls

  increases, p = 0.1

  and possibly in rs3212227 in IL12(p40) (C; P-trend=0.1) and tagSNP rs3021094 in IL10 (C; P-trend=0.1)

  PMID:28317149 · one of two readings recorded this

• serum PSA trend with minor allele number in controls

  increases, p = 0.02

  PSA concentration increased with number of minor alleles in rs2069762 in IL2 (G; P-trend=0.02), rs4073 in IL8 (A; P-trend=0.03)

  PMID:28317149 · one of two readings recorded this

• serum PSA trend with minor allele number in controls

  increases, p = 0.03

  PSA concentration increased with number of minor alleles in rs2069762 in IL2 (G; P-trend=0.02), rs4073 in IL8 (A; P-trend=0.03)

  PMID:28317149 · one of two readings recorded this

• serum PSA trend with minor allele number in controls

  decreases, p = 0.08

  PSA concentration possibly decreased with increasing number of minor alleles of rs1800629 in TNFA (A; P-trend=0.08)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk, IL10 haplotype ATTCCGT vs most common haplotype

  no effect

  appeared to be associated with risk of total (OR=2.11, 95% CI 0.97–4.63), lower- (OR=2.39, 95%CI 1.03–5.56), and higher- (OR=1.89, 95% CI 0.64–5.59) grade disease

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  The minor allele (T) of rs2430561 in IFNG was positively associated with risk of total (OR=1.20, 95% CI 0.99–1.46, P-trend=0.1) and higher-grade (OR=1.33 95%CI 1.02–1.74; P-trend=0.04)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  The minor allele (T) of rs1800871 in IL10 was possibly positively associated with total prostate cancer (OR=1.25, CI: 0.99–1.58, P-trend=0.1) and lower-grade disease (OR=1.26, CI: 0.96–1.64, P-trend=0.09)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  the minor allele (A) of rs1800872 in IL10 was possibly positively associated with overall prostate cancer (OR=1.20, CI: 0.99–1.46, P-trend=0.1) and lower-grade (OR=1.20, CI: 0.96–1.50, P-trend=0.09)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.06

  and possibly inversely associated with overall prostate cancer (OR=0.85, 95% CI 0.72–1.00; P-trend= 0.06)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  The minor allele (T) of rs1143634 in IL1β was possibly inversely associated with total prostate cancer (OR=0.84, CI: 0.70–1.02, P-trend=0.1) and lower-grade (OR=0.82, CI: 0.66–1.02, P-trend=0.07)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  The minor allele (A) of rs4073 in IL8 was possibly inversely associated with total prostate cancer (OR=0.89, CI: 0.75–1.04, P-trend=0.1) and higher-grade disease (OR=0.81, CI: 0.64–1.01, P-trend=0.06)

  PMID:28317149 · one of two readings recorded this

• total prostate cancer risk per minor allele, finasteride arm

  no effect, p = 0.1

  The minor allele (C) of rs3747531 in MSR1 was possibly inversely associated with total (OR=0.77, 95% CI 0.55–1.08, P-trend=0.1) and especially higher-grade (OR=0.55, 95% CI 0.32–0.95, P-trend=0.03)

  PMID:28317149 · one of two readings recorded this

• incidence of renal cell carcinoma by questionnaire and medical record confirmation, self-reported finasteride use versus non-use, Cox proportional hazards in the PLCO screening trial cohort

  no effect, HR 1.12, 95% CI 0.83-1.5, p=0.47, p = 0.47

  Not recorded as a finding: this platform holds no node for the endpoint

  In multivariable main effects analysis, finasteride did not have an association with increased or decreased incidence of RCC in men (HR 1.12, 95% CI 0.83, 1.5, p=0.47) adjusted for smoking, age, study arm, education, body mass index, race/ethnicity, family history of renal cancer, and diabetes.

  PMID:28338531 · one of two readings recorded this

• incidence of renal cell carcinoma by self-reported finasteride use in men, Cox proportional hazards, PLCO screening trial cohort

  no effect, HR 1.12, 95% CI 0.83, 1.5, p = 0.47

  Not recorded as a finding: this platform holds no node for the endpoint

  In multivariable main effects analysis, finasteride did not have an association with increased or decreased incidence of RCC in men (HR 1.12, 95% CI 0.83, 1.5, p=0.47) adjusted for smoking, age, study arm, education, body mass index, race/ethnicity, family history of renal cancer, and diabetes.

  PMID:28338531 · one of two readings recorded this

• prevalence of self-reported finasteride use in men

  n = 73694

  Eight percent (n=6,117 / 73,694) of men in the PLCO trial reported use of Finasteride via questionnaire

  PMID:28338531 · one of two readings recorded this

• prevalence of self-reported oral contraceptive use in women

  n = 75989

  Approximately 54 percent of women (n=40,997/75,989) in the PLCO trial reported use of oral contraceptives via questionnaire

  PMID:28338531 · one of two readings recorded this

• renal cell carcinoma incidence, multivariable Cox model, finasteride use in men

  no effect, p = 0.47

  In multivariable main effects analysis, finasteride did not have an association with increased or decreased incidence of RCC in men (HR 1.12, 95% CI 0.83, 1.5, p=0.47)

  PMID:28338531 · one of two readings recorded this

• renal cell carcinoma incidence, multivariable Cox model, oral contraceptive use in women

  no effect, p = 0.3

  contraceptive use did not have an association with increased or decreased incidence of RCC in women (HR 1.03, 95% CI 0.97,1.1, p=0.30)

  PMID:28338531 · one of two readings recorded this

• renal cell carcinoma incidence, univariable, finasteride-exposed vs unexposed men

  no effect, p = 0.12

  Only 52 (10.6%) of the 492 men diagnosed with renal cancer had self-reported exposure to finasteride and was not significant in univariable analysis (52/6169; 0.84% vs. 440/66454; 0.67%, p=0.12)

  PMID:28338531 · one of two readings recorded this

• renal cell carcinoma incidence, univariable, oral contraceptive-exposed vs unexposed women

  no effect, p = 0.36

  136 (52.1%) of the 261 women diagnosed with renal cancer had self-reported exposure to OCT and was not significant in univariable analysis (136/40,997; 0.33% vs. 125/34992; 0.36%, p=0.36)

  PMID:28338531 · one of two readings recorded this

• age, baseline characteristic

  no effect, p = 0.286

  Mean pt age (SD) | 64.62 (4.95) | 65.37 (4.25) | 0.286

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day change in PCA3 for prostate cancer on biopsy

  no effect, p = 0.72

  the 90-day change in PCA3 and T2:ERG did not discriminate men with and without cancer (AUC 51% (95% CI 43 to 60%, p = 0.72) and 48% (95% CI 44 to 60%)

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day change in PCA3 for prostate cancer on biopsy

  no effect, p = 0.55

  the 90-day change in PCA3 and T2:ERG did not predict cancer status (AUC ~50%, p = 0.55 and p = 0.46, respectively)

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day change in T2:ERG for prostate cancer on biopsy

  no effect

  the 90-day change in PCA3 and T2:ERG did not discriminate men with and without cancer (AUC 51% (95% CI 43 to 60%, p = 0.72) and 48% (95% CI 44 to 60%)

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day change in T2:ERG for prostate cancer on biopsy

  no effect, p = 0.46

  the 90-day change in PCA3 and T2:ERG did not predict cancer status (AUC ~50%, p = 0.55 and p = 0.46, respectively)

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day PSA for prostate cancer on biopsy

  no effect, p = 0.43

  but the 90-day PSA did not predict cancer status (AUC 53%, p = 0.43)

  PMID:30300367 · one of two readings recorded this

• AUC of 90-day T2:ERG vs 50% for prostate cancer on biopsy

  unclear, p = 0.02

  in the placebo arm, only the 90-day T2:ERG AUC was significantly different than 50% (p = 0.02)

  PMID:30300367 · one of two readings recorded this

• AUC of baseline PSA for prostate cancer on biopsy

  unclear, p = 0.04

  In the finasteride group, PSA at baseline had a slight discriminative ability (AUC 58%, p = 0.04)

  PMID:30300367 · one of two readings recorded this

• Gleason score 6 on biopsy, number of patients

  no effect

  6 | 56 (24.0) | 13 (22.0)

  PMID:30300367 · one of two readings recorded this

• Gleason score 7 on biopsy, number of patients

  no effect

  7 | 48 (20.6) | 14 (23.7)

  PMID:30300367 · one of two readings recorded this

• Gleason score 8 on biopsy, number of patients

  no effect

  8 | 8 (3.4) | 1 (1.7)

  PMID:30300367 · one of two readings recorded this

• Gleason score 9 on biopsy, number of patients

  no effect

  9 | 1 (0.4) | 0 (0.0)

  PMID:30300367 · one of two readings recorded this

• independent predictive value of baseline PCA3 for prostate cancer on biopsy

  increases, p = 0.001

  Baseline | PCA3 Score | 1.12 | [1.05, 1.2] | <0.001

  PMID:30300367 · one of two readings recorded this

• independent predictive value of baseline T2:ERG for prostate cancer on biopsy

  increases, p = 0.001

  T2 Score | 1.04 | [1.02, 1.07] | <0.001

  PMID:30300367 · one of two readings recorded this

• independent predictive value of final PCA3 for prostate cancer on biopsy

  increases, p = 0.008

  Final | PCA3 Score | 1.09 | [1.02, 1.17] | 0.008

  PMID:30300367 · one of two readings recorded this

• independent predictive value of final T2:ERG for prostate cancer on biopsy

  increases, p = 0.001

  T2 Score | 1.05 | [1.02, 1.07] | <0.001

  PMID:30300367 · one of two readings recorded this

• independent predictive value of PCA3 ratio for prostate cancer on biopsy

  no effect, p = 0.895

  Ratio | PCA3 Score | 1.01 | [0.91, 1.11] | 0.895

  PMID:30300367 · one of two readings recorded this

• independent predictive value of T2:ERG ratio for prostate cancer on biopsy

  no effect, p = 0.841

  T2 Score | 1.00 | [0.97, 1.03] | 0.841

  PMID:30300367 · one of two readings recorded this

• mean PSA, baseline characteristic

  no effect, p = 0.599

  Mean PSA (SD) | 5.7 (2.0) | 5.6 (1.9) | 0.599

  PMID:30300367 · one of two readings recorded this

• PCA3 score, 90-day final, median by cancer status

  unclear

  Final | 17.26 | 31.24 | 0.63 | 16.99 | 65.52 | 0.8

  PMID:30300367 · one of two readings recorded this

• PCA3 score, 90-day final, median by cancer status

  unclear

  Final | 17.26 | 31.24 | 0.63 | 16.99 | 65.52 | 0.8

  PMID:30300367 · one of two readings recorded this

• PCA3 score, baseline, median by cancer status

  unclear

  PCA3 Score | Baseline | 23.4 | 39.65 | 0.65 | 12.89 | 65.79 | 0.84

  PMID:30300367 · one of two readings recorded this

• PCA3 score, baseline, median by cancer status

  unclear

  PCA3 Score | Baseline | 23.4 | 39.65 | 0.65 | 12.89 | 65.79 | 0.84

  PMID:30300367 · one of two readings recorded this

• PCA3 score, ratio of final to baseline, median by cancer status

  no effect

  Ratio | 0.74 | 0.75 | 0.51 | 1.01 | 0.96 | 0.45

  PMID:30300367 · one of two readings recorded this

• PCA3 score, ratio of final to baseline, median by cancer status

  no effect

  Ratio | 0.74 | 0.75 | 0.51 | 1.01 | 0.96 | 0.45

  PMID:30300367 · one of two readings recorded this

• percent change in PCA3 from baseline to 90 days

  decreases, p = 0.001

  were -25 [-47, +9]%, -26 [-50, +8] %, and -25 [-48, +9] % (all p-values<0.001)

  PMID:30300367 · one of two readings recorded this

• percent change in PCA3 from baseline to 90 days

  decreases, p = 0.001

  were -25 [-47, +9]%, -26 [-50, +8] %, and -25 [-48, +9] % (all p-values<0.001)

  PMID:30300367 · one of two readings recorded this

• percent change in PCA3 from baseline to 90 days

  decreases, p = 0.001

  were -25 [-47, +9]%, -26 [-50, +8] %, and -25 [-48, +9] % (all p-values<0.001)

  PMID:30300367 · one of two readings recorded this

• percent change in PSA from baseline to 90 days

  decreases, p = 0.0001

  in men with PCa (-51%, [–60, –38]%), without PCa (-47%, [–59, –37] %) and all men (49%, [–60, –37] %) indicate statistically significant decreases (p<0.0001)

  PMID:30300367 · one of two readings recorded this

• percent change in PSA from baseline to 90 days

  decreases, p = 0.0001

  in men with PCa (-51%, [–60, –38]%), without PCa (-47%, [–59, –37] %) and all men (49%, [–60, –37] %) indicate statistically significant decreases (p<0.0001)

  PMID:30300367 · one of two readings recorded this

• percent change in PSA from baseline to 90 days

  decreases, p = 0.0001

  in men with PCa (-51%, [–60, –38]%), without PCa (-47%, [–59, –37] %) and all men (49%, [–60, –37] %) indicate statistically significant decreases (p<0.0001)

  PMID:30300367 · one of two readings recorded this

• percent change in T2:ERG from baseline to 90 days

  no effect, p = 0.05

  The median, [Q1, Q3] percent change for T2:ERG in men with PCa (-33 [-77, +166]%) and without PCa (0 [-70, +136,]%) were not significantly different from 0 (p>0.05)

  PMID:30300367 · one of two readings recorded this

• percent change in T2:ERG from baseline to 90 days

  no effect, p = 0.05

  The median, [Q1, Q3] percent change for T2:ERG in men with PCa (-33 [-77, +166]%) and without PCa (0 [-70, +136,]%) were not significantly different from 0 (p>0.05)

  PMID:30300367 · one of two readings recorded this

• proposed PCA3 inflation factor for men on finasteride

  unclear

  an inflation factor of 1.33 = 100/(100–25%) for PCA3

  PMID:30300367 · one of two readings recorded this

• proposed PSA inflation factor for men on finasteride

  unclear

  an inflation factor of 2.0 = 100/(100–49%) for PSA would be appropriate

  PMID:30300367 · one of two readings recorded this

• prostate cancer diagnosed on 3-month biopsy, number of patients

  no effect

  Yes | 116 (49.8) | 28 (47.5)

  PMID:30300367 · one of two readings recorded this

• PSA, 90-day final, median by cancer status

  no effect

  Final | 2.6 | 2.7 | 0.53 | 4.1 | 4.9 | 0.61

  PMID:30300367 · one of two readings recorded this

• PSA, 90-day final, median by cancer status

  no effect

  Final | 2.6 | 2.7 | 0.53 | 4.1 | 4.9 | 0.61

  PMID:30300367 · one of two readings recorded this

• PSA, baseline, median by cancer status

  unclear

  PSA | Baseline | 5.03 | 5.43 | 0.58 | 5.1 | 5.15 | 0.54

  PMID:30300367 · one of two readings recorded this

• PSA, baseline, median by cancer status

  unclear

  PSA | Baseline | 5.03 | 5.43 | 0.58 | 5.1 | 5.15 | 0.54

  PMID:30300367 · one of two readings recorded this

• PSA, ratio of final to baseline, median by cancer status

  decreases

  Ratio | 0.53 | 0.5 | 0.47 | 0.82 | 0.87 | 0.61

  PMID:30300367 · one of two readings recorded this

• PSA, ratio of final to baseline, median by cancer status

  decreases

  Ratio | 0.53 | 0.5 | 0.47 | 0.82 | 0.87 | 0.61

  PMID:30300367 · one of two readings recorded this

• serum PSA change from baseline to 90 days on finasteride 5 mg daily (secondary outcome), with placebo arm of 59 biopsied men

  decreases, percent decrease of PSA relative to baseline within the finasteride arm; no between-arm test stated in prose

  Not recorded as a finding: the result compares a group with itself, not with a control

  These results suggest that finasteride substantially reduces PCA3 and PSA, potentially causing underestimated risk calculations using these biomarkers.

  PMID:30300367 · one of two readings recorded this

• serum PSA change from baseline to 90 days on finasteride 5 mg daily, with a placebo arm (4:1 allocation); also urinary PCA3 and TMPRSS2:ERG

  decreases

  Not recorded as a finding: the result compares a group with itself, not with a control

  These results suggest that finasteride substantially reduces PCA3 and PSA, potentially causing underestimated risk calculations using these biomarkers.

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, 90-day final, median by cancer status

  unclear

  Final | 1.68 | 8.77 | 0.63 | 8.34 | 26.09 | 0.68

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, 90-day final, median by cancer status

  unclear

  Final | 1.68 | 8.77 | 0.63 | 8.34 | 26.09 | 0.68

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, baseline, median by cancer status

  unclear

  T2:ERG Score | Baseline | 2.64 | 6.82 | 0.62 | 1.81 | 10.07 | 0.62

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, baseline, median by cancer status

  unclear

  T2:ERG Score | Baseline | 2.64 | 6.82 | 0.62 | 1.81 | 10.07 | 0.62

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, ratio of final to baseline, median by cancer status

  no effect

  Ratio | 1 | 0.67 | 0.48 | 1 | 1.72 | 0.56

  PMID:30300367 · one of two readings recorded this

• T2:ERG score, ratio of final to baseline, median by cancer status

  no effect

  Ratio | 1 | 0.67 | 0.48 | 1 | 1.72 | 0.56

  PMID:30300367 · one of two readings recorded this

• high-grade prostate cancer (Gleason 7 or higher), finasteride vs placebo (primary PCPT result, cited)

  increases

  The high-grade prostate cancer, defined as a Gleason score of 7 or higher, was more common in the finasteride arm (relative risk 1.27, 95% confidence interval [1.07,1.50])

  PMID:30538099 · one of two readings recorded this

• high-grade prostate cancer risk, finasteride vs placebo (case-only relative risk)

  decreases

  Notably, men carrying GG genotype had a 55% reduction of risk to develop high-grade prostate cancer when taking finasteride (RR=0.45, 95% C.I. [0.27,0.75])

  PMID:30538099 · one of two readings recorded this

• high-grade prostate cancer risk, finasteride vs placebo (classification tree)

  increases

  while the third subgroup with at least a C allele in both loci had a substantially increased risk of developing high-grade prostate cancer (RR=2.21)

  PMID:30538099 · one of two readings recorded this

• high-grade prostate cancer risk, finasteride vs placebo (classification tree)

  decreases

  a small subgroup of men with rs1052536 genotype TT and rs472402 genotype CC or CG have reduced risk by finasteride (RR=0.54)

  PMID:30538099 · one of two readings recorded this

• low-grade prostate cancer risk, finasteride vs placebo (case-only relative risk)

  decreases

  These men also had a decreased risk to develop low-grade prostate cancer when taking finasteride (RR=0.69, 95% C.I. [0.51,0.92])

  PMID:30538099 · one of two readings recorded this

• prostate cancer prevalence over seven years, finasteride vs placebo (primary PCPT result, cited)

  decreases

  The primary results from PCPT were published in 2003, that finasteride reduced the prevalence of prostate cancer by 24.8% (95% confidence interval [18.6%, 30.6%])

  PMID:30538099 · one of two readings recorded this

• risk of high-grade prostate cancer (Gleason 7 or higher) with finasteride versus placebo, by SRD5A1 rs472402 genotype, case-only analysis within the Prostate Cancer Prevention Trial

  decreases, RR 0.45, 95% CI 0.27-0.75 in the GG genotype subgroup

  Not recorded as a finding: every result is a subgroup, with no whole-population estimate

  Notably, men carrying GG genotype had a 55% reduction of risk to develop high-grade prostate cancer when taking finasteride (RR=0.45, 95% C.I. [0.27,0.75]), contrary to the reported overall hazardous intent-to-treat effect.

  PMID:30538099 · one of two readings recorded this

• risk of high-grade prostate cancer (Gleason score above 6) with finasteride versus placebo, by SRD5A1 rs472402 genotype, case-only analysis of PCPT cases

  decreases, RR=0.45, 95% C.I. [0.27,0.75] in men carrying the GG genotype

  Not recorded as a finding: every result is a subgroup, with no whole-population estimate

  Notably, men carrying GG genotype had a 55% reduction of risk to develop high-grade prostate cancer when taking finasteride (RR=0.45, 95% C.I. [0.27,0.75]), contrary to the reported overall hazardous intent-to-treat effect.

  PMID:30538099 · one of two readings recorded this

• rs472402-finasteride interaction, high-grade prostate cancer (univariate case-only p-value)

  modulates, p = 0.00008

  ranging from 0.09 (rs3736544) to 0.00008 (rs472402, the SNP identified in Figure 1a)

  PMID:30538099 · one of two readings recorded this

• rs472402-finasteride interaction, low-grade prostate cancer

  no effect, p = 0.08

  the estimated case-only interaction between rs472402 and finasteride for low-grade cancer is not significant (p-value=0.08)

  PMID:30538099 · one of two readings recorded this

• share of PCPT participants with high-grade risk decreased by finasteride (random forest, RR<1)

  decreases

  There were estimated 37% of PCPT participants whose risk of high-grade prostate cancer were decreased by finasteride (RR<1)

  PMID:30538099 · one of two readings recorded this

• share of PCPT participants with high-grade risk decreased by more than 25% by finasteride (random forest, RR<0.75)

  decreases

  26% of participants whose risk of high-grade prostate cancer were decreased by more than 25% (RR<0.75)

  PMID:30538099 · one of two readings recorded this

• altered libido

  no effect, p = 0.54

  the 95% CI was 0.66–2.20 and the OR was 1.12 (P=0.54)

  PMID:30863034 · one of two readings recorded this

• ejaculation disorders

  no effect, p = 0.58

  A fixed-effects model revealed an OR of 0.75 and 95% CI of 0.28–2.05 (P=0.58)

  PMID:30863034 · one of two readings recorded this

• erectile dysfunction

  no effect, p = 0.7

  A fixed-effects model showed an OR of 1.18 and 95% CI of 0.52–2.68 (P=0.70)

  PMID:30863034 · one of two readings recorded this

• investigator's assessment of global photographs, frontal view

  increases, p = 0.01

  At the frontal scalp, the MD was 0.63 and 95% CI was 0.13–1.13 (P=0.01)

  PMID:30863034 · one of two readings recorded this

• investigator's assessment of global photographs, vertex view

  increases, p = 0.02

  For the vertex views, a random-effects model showed an MD of 0.68 and 95% CI of 0.13–1.23 (P=0.02)

  PMID:30863034 · one of two readings recorded this

• mean change in total hair count, dutasteride versus finasteride, 24 weeks; altered libido, erectile dysfunction, ejaculation disorders

  increases, MD 28.57, 95% CI 18.75-38.39 (dutasteride over finasteride)

  Not recorded as a finding: the comparison was against another active treatment

  A random-effects model was used to assess these RCTs, the MD was 28.57 and 95% CI was 18.75–38.39 (P<0.00001).

  PMID:30863034 · one of two readings recorded this

• mean change in total hair count, dutasteride versus finasteride, 24 weeks

  Not recorded as a finding: the comparison was against another active treatment

  Hence, this result suggested that dutasteride showed significant increase in the total hair count compared with finasteride.

  PMID:30863034 · one of two readings recorded this

• mean change in total hair count

  increases, p = 0.00001

  A random-effects model was used to assess these RCTs, the MD was 28.57 and 95% CI was 18.75–38.39 (P<0.00001)

  PMID:30863034 · one of two readings recorded this

• panel global photographic assessment, frontal view

  increases, p = 0.00001

  At the frontal scalp, the MD was 0.25 and 95% CI was 0.18–0.31 (P<0.00001)

  PMID:30863034 · one of two readings recorded this

• panel global photographic assessment, vertex view

  increases, p = 0.00001

  For the vertex views, a fixed-effects model showed that the MD was 0.17 and 95% CI was 0.09–0.24 (P<0.00001)

  PMID:30863034 · one of two readings recorded this

• subjects' assessment

  increases, p = 0.003

  the MD was 0.56 and 95% CI was 0.18–0.94 (P=0.003)

  PMID:30863034 · one of two readings recorded this

• prostate cancer incidence

  decreases

  with an overall combined OR for the finasteride and placebo groups of 0.70 [0.51, 0.96]

  PMID:32282699 · one of two readings recorded this

• high-grade prostate cancer incidence, pooled OR

  combined OR 2.10 [1.85, 2.38]

  Not recorded as a finding: no outcome node for high-grade (Gleason) prostate cancer; prostate-cancer-incidence is any histologically confirmed cancer

  The overall combined OR for the finasteride and placebo groups was 2.10 [1.85, 2.38].

  PMID:32282699 · one of two readings recorded this

• high-grade prostate cancer incidence

  increases

  The overall combined OR for the finasteride and placebo groups was 2.10 [1.85, 2.38]

  PMID:32282699 · one of two readings recorded this

• high-grade prostate cancer rate, pooled OR finasteride vs placebo

  increases, overall combined OR 2.10 [1.85, 2.38]

  Not recorded as a finding: no outcome node for high-grade prostate cancer; prostate-cancer-incidence covers histologically confirmed diagnoses of any grade

  The overall combined OR for the finasteride and placebo groups was 2.10 [1.85, 2.38].

  PMID:32282699 · one of two readings recorded this

• publication bias (Egger regression test)

  no effect, p = 0.05

  Egger regression test also indicated little evidence of publication bias (P >.05) (Table 2)

  PMID:32282699 · one of two readings recorded this

• adjusted mean change from baseline in target area hair count (TAHC)

  increases

  At week 12, a statistically significant increase from baseline in TAHC relative to placebo was observed with topical finasteride

  PMID:34634163 · one of two readings recorded this

• adjusted mean change from baseline in target area hair count (TAHC)

  increases, p = 0.001

  At week 24, the adjusted mean change from baseline in TAHC was significantly greater with topical finasteride than with placebo (20.2 vs. 6.7 hairs; P < 0.001)

  PMID:34634163 · one of two readings recorded this

• adjusted mean change from baseline in target area hair count (TAHC)

  increases, p = 0.012

  the adjusted mean change from baseline in TAHC at week 24 was significantly greater with topical finasteride than placebo (16.3 vs. 6.3 hairs; p = 0.012) and numerically similar to that with oral finasteride (18.7 hairs; Fig. 4)

  PMID:34634163 · one of two readings recorded this

• adjusted mean change from baseline in target area hair count (TAHC)

  no effect

  and was numerically similar to that with oral finasteride (21.1 hairs; Fig. 3)

  PMID:34634163 · one of two readings recorded this

• adjusted mean change from baseline in target area hair count (TAHC)

  no effect

  the adjusted mean change from baseline in TAHC at week 24 was significantly greater with topical finasteride than placebo (16.3 vs. 6.3 hairs; p = 0.012) and numerically similar to that with oral finasteride (18.7 hairs; Fig. 4)

  PMID:34634163 · one of two readings recorded this

• baseline target area hair count (TAHC)

  Mean TAHC at baseline was similar among treatment groups: 201.0 ± 67.6 hairs for topical finasteride, 204.8 ± 67.2 hairs for placebo and 201.9 ± 72.9 hairs for oral finasteride

  PMID:34634163 · one of two readings recorded this

• baseline target area hair width (TAHW)

  Mean TAHW at baseline was also similar, with values of 44.4, 46.3 and 46.0 µm, respectively

  PMID:34634163 · one of two readings recorded this

• blinded-assessor change in patient hair growth/loss at the vertex

  no effect

  Week 24 | 0.2 (0.09) | 0.1 (0.09) | 0.3 (0.12)

  PMID:34634163 · one of two readings recorded this

• change from baseline in target area hair count (TAHC) at week 24 in a 1 cm2 vertex area, counted on macrophotographs; topical finasteride 0.25% spray versus placebo, oral finasteride 1 mg as reference arm

  increases, adjusted mean change 20.2 vs 6.7 hairs, topical finasteride versus placebo

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  At week 24, the adjusted mean change from baseline in TAHC was significantly greater with topical finasteride than with placebo (20.2 vs. 6.7 hairs; P < 0.001), and was numerically similar to that with oral finasteride (21.1 hairs; Fig. 3).

  PMID:34634163 · one of two readings recorded this

• change from baseline in target area hair width (TAHW)

  no effect

  Week 24 | −0.81 (0.35) | −1.53 (0.37) | 0.72 (0.47)

  PMID:34634163 · one of two readings recorded this

• investigator-assessed change in patient hair growth/loss at the vertex

  increases, p = 0.001

  The investigator‐assessed adjusted mean change from baseline to week 24 in patient hair growth/loss at the vertex was statistically significantly greater with topical finasteride than placebo (0.8 vs. 0.3, P < 0.001)

  PMID:34634163 · one of two readings recorded this

• investigator-assessed change in patient hair growth/loss at the vertex

  no effect

  Week 24 | 0.8 (0.09) * | 0.3 (0.09) | 0.7 (0.12)

  PMID:34634163 · one of two readings recorded this

• responders, blinded-assessor assessment

  increases, p = 0.02

  Blinded‐assessor assessment (%) | 26.0 | 16.0 | 28.6 | 0.02

  PMID:34634163 · one of two readings recorded this

• responders, investigator assessment

  increases, p = 0.005

  Investigator assessment (%) | 42.0 | 27.6 | 35.7 | <0.005

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ hair appearance

  increases, p = 0.015

  Hair appearance | 40.9 | 28.7 | 36.9 | 0.015

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ hair growth

  no effect, p = 0.12

  Hair growth | 39.8 | 32.0 | 31.0 | 0.12

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ overall change

  no effect, p = 0.13

  Overall change | 26.5 | 19.9 | 25.0 | 0.13

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ satisfaction with front hair line

  increases, p = 0.007

  Satisfaction – front hair line | 21.6 | 11.1 | 17.9 | 0.007

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ satisfaction with head top

  no effect, p = 0.13

  Satisfaction – head top | 26.0 | 19.3 | 23.8 | 0.13

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ slow down hair loss

  increases, p = 0.05

  Slow down hair loss | 41.4 | 31.5 | 40.5 | <0.05

  PMID:34634163 · one of two readings recorded this

• responders, MHGQ smaller bald spot

  no effect, p = 0.069

  Smaller bald spot | 29.3 | 21.0 | 31.0 | 0.069

  PMID:34634163 · one of two readings recorded this

• self-administered MHGQ overall score

  no effect

  Week 24 | 2.8 (0.75) | 3.0 (0.95) | 2.9 (0.89)

  PMID:34634163 · one of two readings recorded this

• serum DHT concentration, adjusted mean difference in change from baseline vs oral finasteride

  increases, p = 0.05

  The adjusted mean difference in the change from baseline in serum DHT concentrations was statistically significant between topical finasteride and placebo (P < 0.05), and between topical finasteride and oral finasteride (P < 0.05), at each of weeks 4, 8, 12 and 24

  PMID:34634163 · one of two readings recorded this

• serum DHT concentration, adjusted mean difference in change from baseline vs placebo

  decreases, p = 0.05

  The adjusted mean difference in the change from baseline in serum DHT concentrations was statistically significant between topical finasteride and placebo (P < 0.05), and between topical finasteride and oral finasteride (P < 0.05), at each of weeks 4, 8, 12 and 24

  PMID:34634163 · one of two readings recorded this

• serum DHT concentration at week 24 vs baseline

  decreases

  were 55.6% lower than at baseline in the oral finasteride group (15.75 vs. 35.50 ng/dL, respectively)

  PMID:34634163 · one of two readings recorded this

• serum DHT concentration at week 24 vs baseline

  decreases

  Mean serum DHT concentrations at week 24 were 34.6% lower than at baseline in the topical finasteride group (25.75 vs. 39.32 ng/dL, respectively)

  PMID:34634163 · one of two readings recorded this

• serum DHT concentration, placebo group

  no effect

  Mean serum DHT concentrations in the placebo group remained unaffected during the study (range: 38.5–39.8 ng/dL)

  PMID:34634163 · one of two readings recorded this

• Sexual Dysfunction Questionnaire item scores, topical finasteride vs placebo

  no effect

  There were no significant differences between topical finasteride and placebo in mean scores for any item on the Sexual Dysfunction Questionnaire at week 12 or 24

  PMID:34634163 · one of two readings recorded this

• shift from normal to high plasma testosterone concentration

  In the oral finasteride group, this shift occurred in four (6.7%) patients

  PMID:34634163 · one of two readings recorded this

• baseline target area hair count

  Baseline target area hair count (hairs) | 118.4 ± 30.9 | 116.9 ± 25.9 | –

  PMID:40090937 · one of two readings recorded this

• baseline target area terminal hair count

  Baseline target area terminal hair count (hairs) | 100.5 ± 30.0 | 96.0 ± 29.3 | –

  PMID:40090937 · one of two readings recorded this

• change from baseline in target area (0.903 cm2) hair count and terminal hair count at weeks 12 and 24, by dermatoscopy after hair shaving; topical finasteride spray versus placebo

  increases, terminal hair count change at week 24, 12.49 vs 6.68, LSM difference 5.82, 95% CI 1.48-10.16

  Not recorded as a finding: a node exists but the paper states a different instrument or population

  Meanwhile, as shown in Figure 2B, the LSM (SE) in the target area terminal hair count from baseline had a greater change in the topical finasteride group compared with the placebo group at week 12 (8.69 [1.50] vs. 3.68 [2.04]; LSM [SE] difference, 5.01 [2.45]; 95% CI [0.21–9.81]; P <0.05) and week 24 (12.49 [1.31] vs. 6.68 [1.87]; LSM [SE] difference, 5.82 [2.21]; 95% CI [1.48–10.16]; P <0.01).

  PMID:40090937 · one of two readings recorded this

• change from baseline in target area hair count

  increases, p = 0.05

  In the sensitivity analyses, the change in target area hair count from baseline to week 24 was significantly higher in the topical finasteride group than in the placebo group (P <0.05

  PMID:40090937 · one of two readings recorded this

• change from baseline in target area hair count

  no effect

  At week 12, the change from baseline in target area hair count was higher in the topical finasteride group than in the placebo group, although the difference was not significant (9.24 [1.50] vs. 4.60 [2.12])

  PMID:40090937 · one of two readings recorded this

• change from baseline in target area hair count

  increases, p = 0.05

  At week 24, the LSM (standard error [SE]) change in target area hair count from baseline was significant in the topical finasteride group compared with placebo group (11.96 [1.31] vs. 6.68 [1.84]; LSM [SE] difference, 5.28 [2.20]; 95% CI [0.98–9.59]; P <0.05)

  PMID:40090937 · one of two readings recorded this

The whole record — 230 rows